Research on novel therapeutic methods for breast cancer based on glucose metabolism

• Project/Area Number: 18K08579
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Nagoya City University
• Principal Investigator: Toyama Tatsuya 名古屋市立大学, 医薬学総合研究院(医学), 教授 (30315882)
• Co-Investigator(Kenkyū-buntansha): 遠藤 友美 名古屋市立大学, 医薬学総合研究院(医学), 講師 (20566228) ; 近藤 直人 名古屋市立大学, 医薬学総合研究院(医学), 講師 (90529166)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Project Status: Completed (Fiscal Year 2020)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 乳癌 / FBP1

Outline of Final Research Achievements

We investigated the relationship between FBP1 mRNA expression and clinicopathological factors or prognosis in breast cancer patients, and found a trend toward shorter DFS and OS in low FBP1 mRNA patients. FBP1 expression was higher in patients with positive axillary lymph nodes, and both DFS and OS were significantly worse in patients with positive axillary lymph nodes than in patients with low FBP1 expression.

Academic Significance and Societal Importance of the Research Achievements

FBP1がトリプルネガティブ乳癌の化学療法抵抗性に影響しているのではないかとの仮説のもと本研究が計画したが、FBP1発現とトリプルネガティブ乳癌に対する化学療法の効果に関連は認めなかった。しかし、腋窩リンパ節転移陽性症例でFBP1発現と予後に強い相関を認めたため、その原因について検討する予定である。